Comparison of the cost-effectiveness of letrozole or anastrozole versus tamoxifen as adjuvant therapies for early breast cancer in hormone receptor positive (HR+) postmenopausal women: The UK perspective

被引：0

作者：

Karnon, Jonathan

Delea, Thomas

Papo, Natalie L.

Barghout, Victoria

机构：

[1] Univ Sheffield, Sch Hlth & Related Res, Sheffield S10 2TN, S Yorkshire, England

[2] Policy Anal Inc, Brookline, MA USA

[3] Novartis Pharmaceut UK Ltd, Frimley, England

[4] Novartis Pharmaceut Corp, E Hanover, NJ USA

来源：

ANNALS OF ONCOLOGY | 2006年 / 17卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：107 / 107

页数：1

共 50 条

[1] Comparison of the cost-effectiveness of upfront letrozole or anastrozole, or switched exemestane versus tamoxifen for early breast cancer in hormone receptor positive (HR+) postmenopausal women: the UK perspective
Di Trapani, F.
Karnon, J.
Kaura, S.
EJC SUPPLEMENTS, 2007, 5 (04): : 202 - 203
[2] Comparison of the cost-effectiveness of upfront letrozole or anastrozole, or switched exemestane versus tamoxifen for early breast cancer in hormone receptor positive (HR+) postmenopausal women: the UK perspective.
Karnon, J.
Delea, T. E.
Kaura Meng, S.
di Trapani, F.
BREAST CANCER RESEARCH AND TREATMENT, 2006, 100 : S229 - S229
[3] Comparison of the cost-effectiveness of upfront letrozole or anastrozole versus tamoxifen for early breast cancer in hormone receptor positive (HR plus ) postmenopausal women the Cypriot perspective
Andreopoulos, D.
Karnon, J.
Kaura, S.
EJC SUPPLEMENTS, 2008, 6 (07): : 126 - 127
[4] Reflecting time dependency in hazard rates to analyse the cost-effectiveness of letrozole or anastrozole versus tamoxifen as adjuvant therapies for early breast cancer in hormone receptor-positive (HR+) postmenopausal women: The U.S. perspective
Karnon, J.
Mody-Patel, N.
Kaura, S.
JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
[5] Cost-effectiveness analysis of letrozole versus tamoxifen as initial adjuvant therapy in hormone-receptor positive postmenopausal women with early breast cancer: the UK perspective
Karnon, J
Delea, TE
Barghout, V
Thomas, SK
Papo, NL
Johnston, SRD
BREAST CANCER RESEARCH AND TREATMENT, 2005, 94 : S104 - S104
[6] Comparison of cost-effectiveness of aromatase inhibitors letrozole, anastrozole or exemestane versus tamoxifen for early breast cancer in hormone receptor-positive postmenopausal women: Canadian perspective
El Ouagari, K.
Kamon, J.
Kaura, S.
EJC SUPPLEMENTS, 2007, 5 (04): : 210 - 211
[7] Cost-effectiveness analysis of letrozole versus tamoxifen as initial adjuvant therapy in hormone-receptor positive postmenopausal women with early breast cancer in the UK
Karnon, J
Delea, TE
Papo, NL
Barghout, V
Thomas, SK
Johnston, SR
VALUE IN HEALTH, 2005, 8 (06) : A43 - A43
[8] Comparison of the cost per distant disease free year gained of upfront letrozole or anastrozole, or switched exemestane versus tamoxifen for early breast cancer in hormone receptor positive (HR+) postmenopausal women: the UK perspective
Karnon, J.
Kaura, S.
di Trapani, F.
BREAST, 2007, 16 : S64 - S64
[9] Cost-effectiveness analysis of anastrozole ('Arimidex') versus tamoxifen as first-line therapy in postmenopausal women with hormone receptor-positive (HR+) advanced breast cancer (ABC): a UK perspective
Simons, R
Bassi, R
Jones, D
Barrett-Lee, P
EUROPEAN JOURNAL OF CANCER, 2002, 38 : S68 - S68
[10] Cost-effectiveness of letrozole versus tamoxifen as initial adjuvant therapy in postmenopausal women with hormone-receptor positive early breast cancer from a Canadian perspective
Delea, Thomas E.
El-Ouagari, Khalid
Karnon, Jonathan
Sofrygin, Oleg
BREAST CANCER RESEARCH AND TREATMENT, 2008, 108 (03) : 375 - 387

← 1 2 3 4 5 →